LEVOBUPIVACAINE KABI 7.5 mg/mL Injectable Solution and Perfusion Solution, Generic

2. What you need to know before you are given Levobupivacaine Kabi

Do not use Levobupivacaine Kabi:

• if you are allergic (hypersensitive) to levobupivacaine, to any other local anaesthetic of the same class or to any of the other ingredients of this medicine (listed in section 6).
• if you have very low blood pressure.
• to numb a part of the body by injecting Levobupivacaine Kabi into a vein.
• to relieve pain by injecting it into the area around the neck of the womb (cervix) during the early stages of labour (paracervical block).
• to treat pain during labour.
• as a local anaesthetic during caesarean section.

Warnings and precautions

Tell your doctor before you are given Levobupivacaine Kabi if you have any of the following conditions or diseases. You may need to be monitored more closely or be given a lower dose.

• if you have any heart disease
• if you have a disease of the nervous system
• if you are weak or ill
• if you are elderly
• if you have liver disease.

Using Levobupivacaine Kabi with other medicines

Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. Tell them if you are taking medicines for:

• irregular heart beats (such as mexiletine)
• fungal infections (such as ketoconazole) as they may affect the metabolism of Levobupivacaine Kabi.
• asthma (such as theophylline) as they may affect how long Levobupivacaine Kabi stays in your body.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Levobupivacaine Kabi 7.5 mg/ml must not be used to relieve pain during labour or as a local anaesthetic during caesarean section.

The effects of Levobupivacaine Kabi on the fetus during the first stages of pregnancy are not known. Therefore, Levobupivacaine Kabi must not be used during the first three months of pregnancy unless your doctor considers it necessary.

It is not known whether levobupivacaine passes into breast milk. However, based on experience with similar drugs, it is expected that only small amounts of levobupivacaine will pass into breast milk. Breast-feeding is therefore possible after using a local anaesthetic.

Driving and using machines

The use of Levobupivacaine Kabi may have a considerable effect on the ability to drive and use machines. You must not drive or use machines until the effects of Levobupivacaine Kabi and the effects of the surgery have worn off. Before you leave the hospital, ask your doctor or nurse if you can drive or use machines.

Levobupivacaine Kabi contains sodium

This medicine contains 3.6 mg of sodium (the main component of cooking/table salt) in each ml. This is equivalent to 0.18% of the maximum daily intake of sodium recommended for an adult.

3. How Levobupivacaine Kabi will be given to you

Your doctor will give you Levobupivacaine Kabi by injection through a needle or through a small tube inserted into your back (epidural). Levobupivacaine Kabi can also be injected into other parts of the body to numb the area to be treated, such as the eye, arm or leg.

Your doctor and nurse will monitor you closely while you are being given Levobupivacaine Kabi.

Dose

The amount of Levobupivacaine Kabi that you will be given and how often it will be given will depend on what it is being used for and your physical condition, age and weight. You will be given the lowest dose that will produce the numbness in the area required. The dose will be carefully calculated by your doctor.

If you are given more Levobupivacaine Kabi than you should

If you are given more Levobupivacaine Kabi than you should, you may experience numbness of the tongue, dizziness, blurred vision, muscle twitching, severe difficulty breathing (including breathing stop) and even convulsions. If you notice any of these symptoms, tell your doctor immediately. In some cases, the administration of too much Levobupivacaine Kabi can also cause low blood pressure, slow heart rate or fast heart rate and changes in your heart rhythm. Your doctor may give you other medicines to help stop these symptoms.

If you have any further questions on the use of this product, ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or nurse immediately if you think you are experiencing any of the following side effects. Some of the side effects of Levobupivacaine Kabi can be serious.

Very common(may affect more than 1 in 10 people):

• feeling tired or weak, difficulty breathing, paleness (these are all signs of anaemia)
• low blood pressure
• nausea

Common(may affect up to 1 in 10 people):

• dizziness
• headache
• vomiting
• back pain
• fever
• post-operative pain

Frequency not known(frequency cannot be estimated from the available data):

• severe allergic reactions (hypersensitivity) causing severe difficulty breathing, difficulty swallowing, hives and very low blood pressure
• allergic reactions (hypersensitivity) recognisable by having red and irritated skin, sneezing, excessive sweating, increased heart rate, fainting or swelling of the face, lips, mouth, tongue or throat
• loss of consciousness
• drowsiness
• blurred vision
• breathing stop
• heart block or heart stop
• local numbness
• numb tongue
• muscle weakness or tremors
• loss of control of urine and faeces
• paralysis
• convulsions
• tingling, numbness or other strange sensation
• prolonged erection of the penis, which can be painful
• nervous disorders which can include drooping eyelids, small pupils (the black centre of the eye), sunken eye socket, sweating and/or flushing of one side of the face.

Bradycardia, tachycardia and changes in heart rhythm which can be seen on an electrocardiogram (ECG) have also been reported as side effects.

In very rare cases, some side effects may occur a long time after Levobupivacaine Kabi is given or may be permanent.

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System of Medicines for Human Use: https://www.notificaram.es. By reporting side effects you can help provide more information on the safety of this medicine.

5. Storage of Levobupivacaine Kabi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month stated.

Your doctor will store this medicine for you.

The solution should be used immediately after opening.

Do not use this medicine if you notice particles in the solution.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What is in Levobupivacaine Kabi

• The active substance is levobupivacaine (as hydrochloride)

Levobupivacaine Kabi 7.5 mg/ml solution for injection or infusion: 1 ml of solution contains 7.5 mg of levobupivacaine (as levobupivacaine hydrochloride). Each 10 ml ampoule contains 75 mg of levobupivacaine as levobupivacaine hydrochloride.

• The other ingredients are water for injections, sodium chloride and a small amount of sodium hydroxide and hydrochloric acid.

This medicine contains an excipient with a known effect (sodium). See section 2 for further information.

pH: 4.0 – 6.0

Osmolality: 272 – 372 mOsmol/l

Appearance and pack size of the product

This medicine is a clear, colourless solution in polypropylene ampoules in sterile blister packs. Each ampoule contains 10 ml of solution. It is supplied in packs of 5, 10 or 20 ampoules.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Marketing authorisation holder:

Fresenius Kabi España S.A.U

C/Marina 16-18,

08005-BARCELONA

Manufacturer:

HP Halden Pharma AS

Svinesundsveien 80

1788 Halden

Norway

This medicine is authorised in the Member States of the European Economic Area under the following names:

Date of last revision of this leaflet:October 2018

Detailed and up-to-date information on this product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

-------------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Levobupivacaine Kabi7.5 mg/ml solution for injection and infusion EFG

Instructions for use/handling

Levobupivacaine Kabi 7.5 mg/ml solution for injection and infusion is for single use only. Discard any unused solution. Use only if the pack is intact.

The solution/dilution should be inspected visually before use. Only clear solutions without visible particles should be used.

A sterile blister pack should be chosen when a sterile ampoule surface is required. The ampoule surface is not sterile if the blister pack is damaged.

Dilutions of standard solutions of levobupivacaine should be made with sodium chloride 9 mg/ml (0.9%) injection solution using aseptic techniques.

It has been shown that 8.4 µg/ml of clonidine, 50 µg/ml of morphine and 2 - 4 µg/ml of fentanyl and 0.4 µg/ml of sufentanil are compatible with levobupivacaine in sodium chloride 9 mg/ml (0.9%) injection solution.

Shelf life after first opening: The product should be used immediately.

Shelf life after dilution:

Chemical and physical stability in use of Levobupivacaine Kabi diluted with 9 mg/ml sodium chloride (0.9%) to a final concentration of 0.625 mg/ml and 1.25 mg/ml, respectively, has been demonstrated for 30 days at 2-8°C or 20-25°C.

Chemical and physical stability in use of Levobupivacaine Kabi diluted with 9 mg/ml sodium chloride (0.9%) to a final concentration of 0.625 mg/ml and 1.25 mg/ml, respectively,

• with 8.4 µg/ml of clonidine hydrochloride, 50 µg/ml of morphine sulphate and 2 - 4 µg/ml of fentanyl citrate for 30 days at 2-8°C or 20-22°C.
• with sufentanil added to a concentration of 0.4 µg/ml for 30 days at 2-8°C or for 7 days at 20-22°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless the dilution and mixing have been prepared in controlled and validated aseptic conditions.

Levobupivacaine Kabi should not be mixed with other medicines except those mentioned above. Dissolving with alkaline solutions such as sodium bicarbonate may cause precipitation.

Experience of the safety of treatment with levobupivacaine for more than 24 hours is limited.

Method of administration

Administration of Levobupivacaine Kabi should only be performed by a doctor who has the necessary training and experience or under their supervision.

For information on dosage, see the Summary of Product Characteristics for this product.

Careful aspiration should be performed before and during injection to prevent intravascular injection.

Aspiration should be repeated before and during administration of a bolus dose, which should be injected slowly and in increments of dose at a rate of 7.5 - 30 mg/min, while monitoring the patient's vital functions and maintaining verbal contact with the patient.

If toxic symptoms appear, the injection should be stopped immediately.

Levobupivacaine Kabi

(Levobupivacaine)

7.5 mg/ml

Read the instructions carefully. Shake until any contents of the neck are removed.

Hold the ampoule in the palm of your hand at waist level. Hold the arrow on the ampoule cap between your thumb and index finger (with your thumb facing outwards). Twist quickly and sharply towards you (in a counter-clockwise direction).

Push the Luer cone of the syringe firmly into the ampoule

Push the ampoule gently towards you with your index finger and withdraw the contents slowly, taking special care at the beginning